Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice

[1]  S. Barni,et al.  Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis , 2019, Journal of immunotherapy.

[2]  N. Tinari,et al.  Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. , 2019, Clinical lung cancer.

[3]  D. Speiser,et al.  Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. , 2019, JAMA oncology.

[4]  Xin Wang,et al.  Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. , 2019, JAMA oncology.

[5]  J. Wolchok,et al.  Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition. , 2019, Journal of Clinical Oncology.

[6]  N. Tinari,et al.  A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable , 2019, Journal of Immunotherapy for Cancer.

[7]  N. Tinari,et al.  Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. , 2019, The oncologist.

[8]  M. Perazella,et al.  Cardiorenal complications of immune checkpoint inhibitors , 2018, Nature Reviews Nephrology.

[9]  Hans Anton Schlößer,et al.  Cytokine release syndrome , 2018, Journal of Immunotherapy for Cancer.

[10]  Richard Pazdur,et al.  Re-Evaluating Eligibility Criteria for Oncology Clinical Trials: Analysis of Investigational New Drug Applications in 2015. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[12]  C. Horak,et al.  Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. , 2016, The Lancet. Oncology.

[13]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[14]  J. Bower,et al.  Cancer-related fatigue—mechanisms, risk factors, and treatments , 2014, Nature Reviews Clinical Oncology.

[15]  J. Bluestone,et al.  Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways , 2008, Immunological reviews.

[16]  A. Abernethy,et al.  Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

[17]  J. Lohr,et al.  T cell tolerance and autoimmunity. , 2004, Autoimmunity reviews.

[18]  G. Ciliberto,et al.  Dual control of C‐reactive protein gene expression by interleukin‐1 and interleukin‐6. , 1989, The EMBO journal.

[19]  P. Bonate.  Effect of correlation on covariate selection in linear and nonlinear mixed effect models , 2017, Pharmaceutical statistics.